JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

JNJ

170.73

-0.23%↓

ABBV

198.59

+0.8%↑

AZN

74.43

-0.13%↓

NVS

117.78

-0.02%↓

ABT

130.77

+0.52%↑

Search

Adaptive Biotechnologies Corp

Затворен

11.07 1.56

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

10.68

Максимум

11.67

Ключови измерители

By Trading Economics

Приходи

3.9M

-30M

Продажби

5M

52M

Марж на печалбата

-56.881

Служители

619

EBITDA

-3.3M

-30M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+19.16% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

503M

1.7B

Предишно отваряне

9.51

Предишно затваряне

11.07

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.08.2025 г., 23:11 ч. UTC

Печалби

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5.08.2025 г., 22:45 ч. UTC

Печалби

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5.08.2025 г., 22:39 ч. UTC

Печалби

Great-West Lifeco Logs Lower 2Q Profit

5.08.2025 г., 21:32 ч. UTC

Печалби

Coupang Posts Higher 2Q Sales Due to Customer Growth

6.08.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6.08.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6.08.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6.08.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5.08.2025 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5.08.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5.08.2025 г., 23:19 ч. UTC

Пазарно говорене

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5.08.2025 г., 23:03 ч. UTC

Пазарно говорене
Печалби

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5.08.2025 г., 22:22 ч. UTC

Печалби

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5.08.2025 г., 22:21 ч. UTC

Печалби

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5.08.2025 г., 22:20 ч. UTC

Печалби

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5.08.2025 г., 22:18 ч. UTC

Печалби

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5.08.2025 г., 22:17 ч. UTC

Печалби

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5.08.2025 г., 22:17 ч. UTC

Печалби

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5.08.2025 г., 22:16 ч. UTC

Печалби

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5.08.2025 г., 22:16 ч. UTC

Печалби

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5.08.2025 г., 22:15 ч. UTC

Печалби

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5.08.2025 г., 22:13 ч. UTC

Печалби

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5.08.2025 г., 22:13 ч. UTC

Печалби

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5.08.2025 г., 22:12 ч. UTC

Печалби

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5.08.2025 г., 22:12 ч. UTC

Печалби

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5.08.2025 г., 21:58 ч. UTC

Печалби

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5.08.2025 г., 21:30 ч. UTC

Печалби

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5.08.2025 г., 21:26 ч. UTC

Печалби

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5.08.2025 г., 21:23 ч. UTC

Печалби

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5.08.2025 г., 21:17 ч. UTC

Печалби

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Сравнение с други в отрасъла

Ценова промяна

Adaptive Biotechnologies Corp Прогноза

Ценова цел

By TipRanks

19.16% нагоре

12-месечна прогноза

Среден 13 USD  19.16%

Висок 13 USD

Нисък 13 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Adaptive Biotechnologies Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

3 ratings

3

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

8.81 / 10.18Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Weak Bullish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.